Sonja Zweegman

32.6k citations

334 papers · 10.4k indexed · 3 hit papers · h-index 55

Hematology top 0.05%
Molecular Biology top 1%
Oncology top 0.5%
Genetics top 0.5%
Immunology top 2%

Co-authors: Niels W.C.J. van de Donk Pieter Sonneveld Henk M. Lokhorst Tuna Mutis Gert J. Ossenkoppele Gerrit Jan Schuurhuis Evangelos Terpos Jacqueline Cloos
Topics: Multiple Myeloma Research and Treatments (189 papers)Protein Degradation and Inhibitors (62 papers)Peptidase Inhibition and Analysis (45 papers)
Cited by: Hematology Oncology Genetics
Journals: The Lancet Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: Netherlands United States Italy

In The Last Decade

Sonja Zweegman

313 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 518 citations Philippe Moreau, Pieter Sonneveld et al. profile →
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2021 460 citations Philippe Moreau, Evangelos Terpos et al. profile →
T-cell-engaging bispecific antibodies in cancer

2023 139 citations Niels W.C.J. van de Donk, Sonja Zweegman profile →

Peers

Countries citing papers authored by Sonja Zweegman

Since Specialization

Citations

This map shows the geographic impact of Sonja Zweegman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonja Zweegman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonja Zweegman more than expected).

Fields of papers citing papers by Sonja Zweegman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonja Zweegman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonja Zweegman. The network helps show where Sonja Zweegman may publish in the future.

Co-authorship network of co-authors of Sonja Zweegman

This figure shows the co-authorship network connecting the top 25 collaborators of Sonja Zweegman. A scholar is included among the top collaborators of Sonja Zweegman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonja Zweegman. Sonja Zweegman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study 2025 ·Blood ·Sonja Zweegman,Fredrik Schjesvold,Alessandra Larocca,Sabrin Tahri,(unknown),(unknown),(unknown),(unknown),(unknown),Mario Boccadoro,Pieter Sonneveld,Niels W.C.J. van de Donk,María-Victoria Mateos	0
2	Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes 2024 ·HemaSphere ·(unknown),(unknown),Kazem Nasserinejad,Mark‐David Levin,Josien C. Regelink,(unknown),(unknown),Matthijs Westerman,Gerjo A. Velders,Koen de Heer,(unknown),Roel J.W. van Kampen,Claudia A.M. Stege,(unknown),Inger S. Nijhof,Ellen van der Spek,Saskia K. Klein,Niels W.C.J. van de Donk,Paula F. Ypma,Sonja Zweegman	5
3	Supportive care in myeloma—when treating the clone alone is not enough 2024 ·Hematology ·Sonja Zweegman,Niels W.C.J. van de Donk	0
4	Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma 2024 ·Blood ·(unknown),Kazem Nasserinejad,Mark‐David Levin,(unknown),(unknown),Josien C. Regelink,Gerjo A. Velders,Matthijs Westerman,(unknown),(unknown),(unknown),Claudia A.M. Stege,(unknown),(unknown),Monique C. Minnema,Pieter Sonneveld,Paula F. Ypma,Niels W.C.J. van de Donk,Sonja Zweegman	0
5	Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity 2024 ·Supportive Care in Cancer ·Nick de Jonge,Jeroen J. W. M. Janssen,Paula F. Ypma,A H E Herbers,(unknown),(unknown),Jody M.W. van den Ouweland,Aart Beeker,Otto Visser,Sonja Zweegman,Nicole M. A. Blijlevens,Michiel A. van Agtmael,Jonne J. Sikkens	2
6	T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement 2024 ·Expert Opinion on Biological Therapy ·Marise R. Heerma van Voss,Remco J. Molenaar,(unknown),Imke H. Bartelink,S. Rubina Baglio,(unknown),(unknown),Sonja Zweegman,Maria T. Kuipers,Niels W.C.J. van de Donk	1
7	Monoclonal Antibodies in the Treatment of Multiple Myeloma 2023 ·Hematology/Oncology Clinics of North America ·Niels W.C.J. van de Donk,Sonja Zweegman	6
8	Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138 2023 ·Clinical Cancer Research ·(unknown),(unknown),Jennemiek van Arkel,(unknown),Afroditi Katsarou,Ruud Ruiter,(unknown),Huipin Yuan,Joost D. de Bruijn,Sonja Zweegman,Niels W.C.J. van de Donk,Richard W.J. Groen,Maria Themeli,Tuna Mutis	10
9	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile 2022 ·Journal of Clinical Oncology ·Davine Hofste op Bruinink,Rowan Kuiper,Mark van Duin,Tom Cupedo,Vincent H. J. van der Velden,Remco M. Hoogenboezem,Bronno van der Holt,H. Berna Beverloo,(unknown),(unknown),Francesca Gay,Annemiek Broijl,Hervé Avet‐Loiseau,Nikhil C. Munshi,Pellegrino Musto,Philippe Moreau,Sonja Zweegman,Niels W.C.J. van de Donk,Pieter Sonneveld	16
10	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis 2021 ·Clinical Cancer Research ·(unknown),(unknown),Afroditi Katsarou,Renée Poels,(unknown),Esther Drent,(unknown),Fengzhi Li,Sonja Zweegman,Niels W.C.J. van de Donk,Maria Themeli,Richard W.J. Groen,Tuna Mutis	47
11	Efficacy and safety of daratumumab combined with all-transretinoic acid in relapsed/refractory multiple myeloma 2021 ·Blood Advances ·Kristine A. Frerichs,Monique C. Minnema,Mark‐David Levin,Annemiek Broijl,Gerard M.J. Bos,Marie José Kersten,Tuna Mutis,Christie P.M. Verkleij,Inger S. Nijhof,(unknown),Saskia K. Klein,Sonja Zweegman,Pieter Sonneveld,Niels W.C.J. van de Donk	27
12	V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma 2021 ·Cancers ·Pim Mutsaers,Hayri E. Balcıoğlu,Rowan Kuiper,Dora Hammerl,Rebecca Wijers,Mark van Duin,Bronno van der Holt,Annemiek Broijl,Walter A. Gregory,Sonja Zweegman,Pieter Sonneveld,Reno Debets	12
13	Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab 2020 ·Clinical Cancer Research ·Kristine A. Frerichs,Marloes E.C. Broekmans,(unknown),Berris van Kessel,Martijn W. Heymans,(unknown),Christie P.M. Verkleij,Rengasamy Boominathan,Bhavesh Vaidya,Jocelyn Sendecki,Amy Axel,François Gaudet,Kodandaram Pillarisetti,Sonja Zweegman,Homer Adams,Tuna Mutis,Niels W.C.J. van de Donk	68
14	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies 2020 ·Cancers ·Christie P.M. Verkleij,(unknown),Marloes E.C. Broekmans,Kristine A. Frerichs,Sonja Zweegman,Tuna Mutis,Natalie Bezman,Niels W.C.J. van de Donk	26
15	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells 2019 ·Clinical Cancer Research ·Esther Drent,Renée Poels,Ruud Ruiter,Niels W.C.J. van de Donk,Sonja Zweegman,Huipin Yuan,Joost D. de Bruijn,Michel Sadelain,Henk M. Lokhorst,Richard W.J. Groen,Tuna Mutis,Maria Themeli	135
16	Carfilzomib for relapsed and refractory multiple myeloma 2019 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),(unknown),Sonja Zweegman,(unknown)	1
17	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab 2017 ·Clinical Cancer Research ·Jakub Krejcik,(unknown),Inger S. Nijhof,Berris van Kessel,Jeroen F. van Velzen,Andries C. Bloem,Marloes E.C. Broekmans,Sonja Zweegman,Johan van Meerloo,René J.P. Musters,Pino J. Poddighe,Richard W.J. Groen,Christopher Chiu,Torben Plesner,Henk M. Lokhorst,A. Kate Sasser,Tuna Mutis,Niels W.C.J. van de Donk	119
18	HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS 2017 ·Data Archiving and Networked Services (DANS) ·Monique C. Minnema,Kazem Nasserinejad,Bouke P. C. Hazenberg,Ute Hegenbart,L. Noens,Paula F. Ypma,Sonja Zweegman,Lidwine W. Tick,Annemiek Broijl,(unknown),Gerard M.J. Bos,(unknown),Pieter Sonneveld,Stefan Schönland	1
19	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma 2016 ·Blood ·Inger S. Nijhof,Tineke Casneuf,(unknown),Berris van Kessel,Amy Axel,Khaja Syed,Richard W.J. Groen,Mark van Duin,Pieter Sonneveld,Monique C. Minnema,Sonja Zweegman,Christopher Chiu,Andries C. Bloem,Tuna Mutis,Henk M. Lokhorst,A. Kate Sasser,Niels W.C.J. van de Donk	275
20	Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review 2013 ·British Journal of Haematology ·Josien C. Regelink,Monique C. Minnema,Evangelos Terpos,Marjolein H. Kamphuis,Pieter G. Raijmakers,(unknown),Ben G. F. Heggelman,(unknown),René H.J. Otten,(unknown),Josée M. Zijlstra,Anne I.J. Arens,(unknown),Otto S. Hoekstra,Reinier Raymakers,Pieter Sonneveld,Raymond Ostelo,Sonja Zweegman	142

About Sonja Zweegman

Sonja Zweegman is a scholar working on Hematology, Genetics and Oncology, having authored 334 papers that have together received 10.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (189 papers), Protein Degradation and Inhibitors (62 papers) and Peptidase Inhibition and Analysis (45 papers). The work is most often cited by research in Hematology (6.5k citations), Oncology (4.6k citations) and Genetics (1.5k citations). Sonja Zweegman has collaborated with scholars based in Netherlands, United States and Italy. Frequent co-authors include Niels W.C.J. van de Donk, Pieter Sonneveld, Henk M. Lokhorst, Tuna Mutis, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis, Evangelos Terpos, Jacqueline Cloos, Meletios Α. Dimopoulos and Philippe Moreau. Their work appears in journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact